Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 7/20 | 0.39 |
| ▸ | CTSS | P25774 | 6/20 | 0.39 |
| ▸ | CTSB | P07858 | 6/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 2/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7690161 | 0.81 | CTSK (0.37) | MAPTGLACTSKCTSSCTSB | |
| SCHEMBL5372334 | 0.79 | CTSC (0.43) | CTSKCTSSCTSBKCNH2JAK2 | |
| SCHEMBL5372333 | 0.75 | JAK2 (0.37) | MAPTGLACTSKCTSSCTSB | |
| SCHEMBL6105917 | 0.72 | CTSS (0.56) | CTSKCTSSCTSB | |
| SCHEMBL6973197 | 0.71 | CTSS (0.43) | CTSKCTSSCTSB | |
| SCHEMBL6968200 | 0.70 | CTSS (0.34) | CTSKCTSSCTSB | |
| SCHEMBL5357537 | 0.70 | CTSS (0.47) | CTSKCTSSCTSBKCNH2 | |
| SCHEMBL5368741 | 0.69 | CTSC (0.46) | CTSKCTSSCTSB | |
| SCHEMBL5368645 | 0.68 | CTSK (0.51) | MAPTCTSKCTSSCTSBALDH1A1 | |
| SCHEMBL5356445 | 0.68 | CTSK (0.49) | CTSKCTSSCTSBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020058809-A1 | Compounds useful as reversible inhibitors of cysteine proteases | EMMANUEL MICHEL JOSE (US) | 2002-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058809-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | MAPT 4375/4885GLA 311/4885CTSK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.